NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.66 -0.03 (-1.78 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.66
Today's Range$1.61 - $1.72
52-Week Range$0.65 - $8.40
Volume256,891 shs
Average Volume1.33 million shs
Market Capitalization$55.47 million
P/E Ratio-0.99
Dividend YieldN/A
Beta1.84

About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics logovTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Debt-to-Equity Ratio-0.09
Current Ratio0.35
Quick Ratio0.35

Price-To-Earnings

Trailing P/E Ratio-0.99
Forward P/E Ratio-1.39
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales187.87
Cash FlowN/A
Price / CashN/A
Book Value($4.53) per share
Price / Book-0.37

Profitability

EPS (Most Recent Fiscal Year)($1.67)
Net Income$-16,140,000.00
Net Margins-639.83%
Return on EquityN/A
Return on Assets-58.08%

Miscellaneous

Employees56
Outstanding Shares32,820,000

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $2.06 million for the quarter, compared to analysts' expectations of $3.14 million. View vTv Therapeutics' Earnings History.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for vTv Therapeutics.

What price target have analysts set for VTVT?

8 equities research analysts have issued 1-year price targets for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they anticipate vTv Therapeutics' stock price to reach $14.7143 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 977,984 shares, a decrease of 32.3% from the April 30th total of 1,444,136 shares. Based on an average daily volume of 1,462,831 shares, the days-to-cover ratio is presently 0.7 days. Approximately 14.0% of the shares of the stock are sold short.

Who are some of vTv Therapeutics' key competitors?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 61)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)
  • Dr. Larry Douglas Altstiel, Exec. VP & Chief Medical Officer (Age 68)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Has vTv Therapeutics been receiving favorable news coverage?

News stories about VTVT stock have trended somewhat positive on Saturday, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. vTv Therapeutics earned a coverage optimism score of 0.03 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.00%), C WorldWide Group Holding A S (0.30%) and Millennium Management LLC (0.29%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Which major investors are buying vTv Therapeutics stock?

VTVT stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., C WorldWide Group Holding A S and Millennium Management LLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $1.66.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $55.47 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]


MarketBeat Community Rating for vTv Therapeutics (VTVT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

vTv Therapeutics (NASDAQ:VTVT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for vTv Therapeutics in the last 12 months. Their average twelve-month price target is $14.7143, suggesting that the stock has a possible upside of 786.40%. The high price target for VTVT is $28.00 and the low price target for VTVT is $4.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.252.252.832.80
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.7143$14.7143$18.40$16.00
Price Target Upside: 786.40% upside1,465.35% upside172.19% upside173.04% upside

vTv Therapeutics (NASDAQ:VTVT) Consensus Price Target History

Price Target History for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018Roth CapitalDowngradeBuy ➝ Neutral$18.00 ➝ $17.00HighView Rating Details
4/10/2018Northland SecuritiesDowngradeOutperform ➝ Market Perform$28.00HighView Rating Details
4/10/2018Seaport Global SecuritiesDowngradeBuy ➝ NeutralHighView Rating Details
4/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$4.00HighView Rating Details
4/10/2018Stifel NicolausDowngradeBuy ➝ HoldHighView Rating Details
12/21/2017Canaccord GenuitySet Price TargetBuy$15.00LowView Rating Details
11/8/2017CitigroupReiterated RatingaddN/AView Rating Details
8/4/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
(Data available from 5/26/2016 forward)

Earnings

vTv Therapeutics (NASDAQ:VTVT) Earnings History and Estimates Chart

Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.45)($0.45)($0.45)
Q2 20181($0.26)($0.26)($0.26)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.16)($0.16)($0.16)

vTv Therapeutics (NASDAQ VTVT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018        
5/15/2018Q1 2018($0.26)($0.3040)$3.14 million$2.06 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.41)($0.44)$0.10 million$0.23 millionViewN/AView Earnings Details
11/1/2017Q3 2017($0.40)($0.38)$0.19 million$0.02 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.4090)$0.19 million$0.01 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.4430)($0.4350)$0.20 million$0.03 millionViewN/AView Earnings Details
2/27/2017Q4 2016($0.14)($0.42)$15.20 million$0.04 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.41)$0.10 million$0.04 millionViewN/AView Earnings Details
8/2/2016Q2 2016($0.58)($0.47)$0.18 millionViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)$0.38 millionViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.45)($0.49)$0.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

vTv Therapeutics (NASDAQ:VTVT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

vTv Therapeutics (NASDAQ VTVT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 15.04%
Insider Trading History for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ VTVT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.03$201,500.00View SEC Filing  
12/7/2017Paul G SavasDirectorBuy15,000$4.56$68,400.0081,781View SEC Filing  
8/22/2017Ronald O PerelmanMajor ShareholderBuy20,000$4.57$91,400.00View SEC Filing  
8/16/2017Ronald O PerelmanMajor ShareholderBuy10,000$4.97$49,700.00View SEC Filing  
8/15/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.72$236,000.00View SEC Filing  
8/11/2017Ronald O PerelmanMajor ShareholderBuy85,000$4.13$351,050.00View SEC Filing  
5/15/2017Paul G SavasDirectorBuy3,000$5.18$15,540.0069,881View SEC Filing  
3/31/2017Paul G SavasDirectorBuy10,000$6.50$65,000.0066,435View SEC Filing  
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.0058,781View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.3452,526View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.0046,522View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.0030,000View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.006,000View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.0020,000View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

vTv Therapeutics (NASDAQ VTVT) News Headlines

Source:
DateHeadline
Seaport Global Securities Analysts Lift Earnings Estimates for vTv Therapeutics Inc (VTVT)Seaport Global Securities Analysts Lift Earnings Estimates for vTv Therapeutics Inc (VTVT)
www.americanbankingnews.com - May 23 at 7:05 AM
vTv Therapeutics (VTVT) Expected to Post Quarterly Sales of $720,000.00vTv Therapeutics (VTVT) Expected to Post Quarterly Sales of $720,000.00
www.americanbankingnews.com - May 19 at 3:56 AM
 Analysts Expect vTv Therapeutics (VTVT) Will Announce Earnings of -$0.33 Per Share Analysts Expect vTv Therapeutics (VTVT) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - May 17 at 2:29 PM
vTv Therapeutics (VTVT) Issues  Earnings Results, Misses Estimates By $0.04 EPSvTv Therapeutics (VTVT) Issues Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 16 at 10:52 AM
BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30
www.reuters.com - May 16 at 9:45 AM
vTv Therapeutics Inc.vTv Therapeutics Inc.
www.streetinsider.com - May 16 at 9:45 AM
VTv Therapeutics: 1Q Earnings SnapshotVTv Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 16 at 9:45 AM
vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent HighlightsvTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights
finance.yahoo.com - May 15 at 4:46 PM
Benzingas Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimers Trial ...Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial ...
www.benzinga.com - May 10 at 4:35 PM
US STOCKS ON THE MOVE-Armo BioSciences, Carvana, L BrandsUS STOCKS ON THE MOVE-Armo BioSciences, Carvana, L Brands
www.nasdaq.com - May 10 at 4:35 PM
vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B ...vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B ...
www.businesswire.com - May 10 at 4:35 PM
BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDABRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA
www.reuters.com - May 10 at 4:35 PM
After-Hours Stock Movers 05/09: (HEAR) (VTVT) (RESN) Higher; (NUAN) (SYNA) (BKNG) Lower (more...)After-Hours Stock Movers 05/09: (HEAR) (VTVT) (RESN) Higher; (NUAN) (SYNA) (BKNG) Lower (more...)
www.streetinsider.com - May 10 at 9:42 AM
vTv Therapeutics (VTVT) Says it will Pre-specify New Subgroup with FDA and Report Phase 3 Part B Results in JunevTv Therapeutics (VTVT) Says it will Pre-specify New Subgroup with FDA and Report Phase 3 Part B Results in June
www.streetinsider.com - May 10 at 9:42 AM
vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in JunevTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June
finance.yahoo.com - May 10 at 9:42 AM
vTv Therapeutics (VTVT) Lifted to "Hold" at ValuEnginevTv Therapeutics (VTVT) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 2:02 PM
vTv Therapeutics (VTVT) Given Consensus Recommendation of "Hold" by AnalystsvTv Therapeutics (VTVT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 5:18 AM
$3.14 Million in Sales Expected for vTv Therapeutics (VTVT) This Quarter$3.14 Million in Sales Expected for vTv Therapeutics (VTVT) This Quarter
www.americanbankingnews.com - May 1 at 1:50 AM
Key executive leaving High Point biotech firm following disappointing trial resultsKey executive leaving High Point biotech firm following disappointing trial results
finance.yahoo.com - April 30 at 9:42 AM
-$0.37 EPS Expected for vTv Therapeutics (VTVT) This Quarter-$0.37 EPS Expected for vTv Therapeutics (VTVT) This Quarter
www.americanbankingnews.com - April 29 at 9:06 PM
Bargain hunters in vTv Therapeutics (+78%) could face capital raise-stoked volatilityBargain hunters in vTv Therapeutics (+78%) could face capital raise-stoked volatility
seekingalpha.com - April 18 at 4:41 PM
vTv Therapeutics shares nearly double following HQ newsvTv Therapeutics shares nearly double following HQ news
www.bizjournals.com - April 18 at 4:41 PM
Bargain hunters jump into vTv Therapeutics, shares up 71%Bargain hunters jump into vTv Therapeutics, shares up 71%
seekingalpha.com - April 17 at 4:50 PM
VTv Therapeutics shares surge 40 percentVTv Therapeutics shares surge 40 percent
finance.yahoo.com - April 17 at 4:50 PM
vTv Therapeutics Fails Late-Stage Alzheimers Study; Is There A Chance For A Comeback?vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A Comeback?
seekingalpha.com - April 16 at 4:23 PM
vTv Therapeutics (VTVT) Short Interest UpdatevTv Therapeutics (VTVT) Short Interest Update
www.americanbankingnews.com - April 14 at 2:29 AM
Zacks: Analysts Anticipate vTv Therapeutics (VTVT) Will Post Quarterly Sales of $3.14 MillionZacks: Analysts Anticipate vTv Therapeutics (VTVT) Will Post Quarterly Sales of $3.14 Million
www.americanbankingnews.com - April 14 at 1:47 AM
vTv Therapeutics (VTVT) Rating Increased to Hold at Zacks Investment ResearchvTv Therapeutics (VTVT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:34 PM
 Analysts Anticipate vTv Therapeutics (VTVT) to Post -$0.37 EPS Analysts Anticipate vTv Therapeutics (VTVT) to Post -$0.37 EPS
www.americanbankingnews.com - April 12 at 11:14 PM
UPDATE: Seaport Global Securities Downgrades vTv Therapeutics (VTVT) to NeutralUPDATE: Seaport Global Securities Downgrades vTv Therapeutics (VTVT) to Neutral
www.streetinsider.com - April 12 at 10:23 AM
FY2019 EPS Estimates for vTv Therapeutics (VTVT) Decreased by AnalystFY2019 EPS Estimates for vTv Therapeutics (VTVT) Decreased by Analyst
www.americanbankingnews.com - April 12 at 8:04 AM
Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)Q1 2018 EPS Estimates for vTv Therapeutics Decreased by Seaport Global Securities (VTVT)
www.americanbankingnews.com - April 12 at 7:24 AM
VTv Therapeutics stock continues to take a hit on failed Alzheimers studyVTv Therapeutics stock continues to take a hit on failed Alzheimer's study
www.bizjournals.com - April 11 at 4:27 PM
Equities Analysts Issue Forecasts for vTv Therapeutics FY2021 Earnings (VTVT)Equities Analysts Issue Forecasts for vTv Therapeutics' FY2021 Earnings (VTVT)
www.americanbankingnews.com - April 11 at 9:25 AM
vTv Therapeutics Crashes on Alzheimer's Drug Study FailurevTv Therapeutics Crashes on Alzheimer's Drug Study Failure
finance.yahoo.com - April 10 at 4:26 PM
Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimers TrialStifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial
finance.yahoo.com - April 10 at 4:26 PM
Mid-Afternoon Market Update: Dow Rises 460 Points; vTv Therapeutics Shares Fall After Failed Alzheimers TrialMid-Afternoon Market Update: Dow Rises 460 Points; vTv Therapeutics Shares Fall After Failed Alzheimer's Trial
feeds.benzinga.com - April 10 at 3:28 PM
vTv Therapeutics (VTVT) Cut to Neutral at Roth CapitalvTv Therapeutics (VTVT) Cut to Neutral at Roth Capital
www.americanbankingnews.com - April 10 at 10:25 AM
After-Hours Stock Movers 04/09: (PAY) (WATT) (PME) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)After-Hours Stock Movers 04/09: (PAY) (WATT) (PME) Higher; (VTVT) (NBEV) (EMKR) Lower (more...)
www.streetinsider.com - April 10 at 9:55 AM
vTv Therapeutics Crashes on Alzheimers Drug Study FailurevTv Therapeutics Crashes on Alzheimer's Drug Study Failure
www.zacks.com - April 10 at 9:55 AM
vTv Therapeutics azeliragon flunks late-stage Alzheimers studyvTv Therapeutics' azeliragon flunks late-stage Alzheimer's study
seekingalpha.com - April 10 at 9:55 AM
vTv Therapeutics (VTVT) STEADFAST Phase 3 Study Evaluating Azeliragon Didnt Meet Either Co-primary Efficacy EndpointvTv Therapeutics (VTVT) STEADFAST Phase 3 Study Evaluating Azeliragon Didn't Meet Either Co-primary Efficacy Endpoint
www.streetinsider.com - April 10 at 9:55 AM
Shares of vTv Therapeutics plummet as Alzheimers study disappointsShares of vTv Therapeutics plummet as Alzheimer's study disappoints
finance.yahoo.com - April 10 at 9:55 AM
Vtv Therapeutics price plummets after disappointing trial resultsVtv Therapeutics price plummets after disappointing trial results
finance.yahoo.com - April 10 at 9:55 AM
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s DiseasevTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
finance.yahoo.com - April 10 at 9:55 AM
vTv Therapeutics (VTVT) Downgraded by Northland SecuritiesvTv Therapeutics (VTVT) Downgraded by Northland Securities
www.americanbankingnews.com - April 10 at 9:16 AM
vTv Therapeutics (VTVT) Downgraded by Seaport Global SecuritiesvTv Therapeutics (VTVT) Downgraded by Seaport Global Securities
www.americanbankingnews.com - April 10 at 8:29 AM
vTv Therapeutics (VTVT) Lowered to Hold at Stifel NicolausvTv Therapeutics (VTVT) Lowered to Hold at Stifel Nicolaus
www.americanbankingnews.com - April 10 at 7:31 AM
Piper Jaffray Downgrades vTv Therapeutics (VTVT) to HoldPiper Jaffray Downgrades vTv Therapeutics (VTVT) to Hold
www.americanbankingnews.com - April 10 at 7:31 AM
Trading in vTv Therapeutics halted pending newsTrading in vTv Therapeutics halted pending news
seekingalpha.com - April 9 at 4:50 PM

SEC Filings

vTv Therapeutics (NASDAQ:VTVT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

vTv Therapeutics (NASDAQ:VTVT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

vTv Therapeutics (NASDAQ VTVT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.